Dateline City:
BOSTON
- 4Q19 total revenues of $1,384.3 million, a 23 percent increase over 4Q18
- 4Q19 GAAP diluted EPS of $4.00; non-GAAP diluted EPS of $2.71
- Received Japanese approval for SOLIRIS® (eculizumab) for neuromyelitis optica spectrum disorder (NMOSD)
- Established ULTOMIRIS® (ravulizumab) as market leader for PNH in U.S., Germany and Japan within first year of launch
- Continued strong SOLIRIS gMG and NMOSD launches, making neurology largest franchise in U.S.
- Expanded pipeline with 19 clinical-stage development programs planned for 2020 across 10 assets, including 2 Factor D inhibitors, following completion of Achillion acquisition
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2019. Total revenues for the full year of 2019 were $4,991.1 million, a 21 percent increase compared to 2018. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $45.1 million, inclusive of hedging activities.
Language:
English
Contact:
Media
Megan Goulart, 857-338-8634
Senior Director, Corporate Communications
Investors
Susan Altschuller, Ph.D., 857-338-8788
Vice President, Investor Relations
Ticker Slug:
Ticker:
ALXN
Exchange:
NASDAQ
